Kingworld Medicines Group Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Li Sheng Zhao
Chief Executive Officer (CEO)
CN¥1.5m
Compensación total
Porcentaje del salario del CEO | 98.5% |
Permanencia del CEO | 16.2yrs |
Participación del CEO | 54.3% |
Permanencia media de la dirección | sin datos |
Promedio de permanencia en la Junta Directiva | 14yrs |
Actualizaciones recientes de la dirección
Recent updates
The Returns On Capital At Kingworld Medicines Group (HKG:1110) Don't Inspire Confidence
Nov 13Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt
Oct 04Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338
May 31Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely
May 22Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings
Apr 29Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338
Apr 23A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Mar 22The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising
Nov 30Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement
Aug 17Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247
May 30The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing
May 11Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247
Apr 03Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture
Feb 07A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Oct 07Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business
Jul 05Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024
Apr 27We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)
Aug 17Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly
Apr 24Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)
Mar 29Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares
Mar 08Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?
Feb 15Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)
Jan 25Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?
Dec 18We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt
Dec 05What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation
Nov 22Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Jun 30 2024 | n/a | n/a | CN¥31m |
Mar 31 2024 | n/a | n/a | CN¥35m |
Dec 31 2023 | CN¥1m | CN¥1m | CN¥38m |
Sep 30 2023 | n/a | n/a | CN¥37m |
Jun 30 2023 | n/a | n/a | CN¥36m |
Mar 31 2023 | n/a | n/a | CN¥29m |
Dec 31 2022 | CN¥1m | CN¥1m | CN¥23m |
Sep 30 2022 | n/a | n/a | CN¥29m |
Jun 30 2022 | n/a | n/a | CN¥35m |
Mar 31 2022 | n/a | n/a | CN¥33m |
Dec 31 2021 | CN¥1m | CN¥1m | CN¥30m |
Sep 30 2021 | n/a | n/a | CN¥26m |
Jun 30 2021 | n/a | n/a | CN¥21m |
Mar 31 2021 | n/a | n/a | CN¥17m |
Dec 31 2020 | CN¥1m | CN¥1m | CN¥12m |
Sep 30 2020 | n/a | n/a | CN¥16m |
Jun 30 2020 | n/a | n/a | CN¥20m |
Mar 31 2020 | n/a | n/a | CN¥32m |
Dec 31 2019 | CN¥2m | CN¥2m | CN¥43m |
Sep 30 2019 | n/a | n/a | CN¥45m |
Jun 30 2019 | n/a | n/a | CN¥46m |
Mar 31 2019 | n/a | n/a | CN¥44m |
Dec 31 2018 | CN¥1m | CN¥1m | CN¥41m |
Sep 30 2018 | n/a | n/a | CN¥49m |
Jun 30 2018 | n/a | n/a | CN¥56m |
Mar 31 2018 | n/a | n/a | CN¥54m |
Dec 31 2017 | CN¥2m | CN¥1m | CN¥51m |
Compensación vs. Mercado: La compensación total ($USD200.40K) de Li Sheng está en línea con el promedio de empresas de tamaño similar en el mercado Hong Kong ($USD233.11K).
Compensación vs. Ingresos: La compensación de Li Sheng ha sido consistente con los resultados de la empresa en el último año.
CEO
Li Sheng Zhao (66 yo)
16.2yrs
Permanencia
CN¥1,452,000
Compensación
Mr. Li Sheng Zhao is a Co-founder of Kingworld Medicines Group Limited and serves as its Chief Executive Officer. Mr. Zhao is responsible for Kingworld Medicines Group's overall strategic planning and busi...
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
Co-Founder | 16.2yrs | CN¥1.45m | 54.31% HK$ 136.9m | |
Co-Founder & Executive Director | 16.2yrs | CN¥1.32m | 15.18% HK$ 38.3m | |
Executive Director | 15.3yrs | CN¥483.00k | 0.45% HK$ 1.1m | |
Independent Non-Executive Director | 14yrs | CN¥285.00k | 0.036% HK$ 90.1k | |
Independent Non-Executive Director | 14yrs | CN¥285.00k | sin datos | |
Independent Non-Executive Director | 11.3yrs | CN¥285.00k | 0.042% HK$ 105.4k | |
Independent Non-Executive Director | less than a year | sin datos | sin datos |
14.0yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de 1110 son experimentados ( 14 años antigüedad media).